$LEG

Leggett & Platt’s (NYSE:LEG) Q2 CY2026 Sales Top Estimates But Stock Drops

Leggett & Platt (NYSE:LEG) reported Q2 CY2026 revenue of $999.7 million, down 5.5% year on year but above analysts’ $982.9 million estimate. Non-GAAP EPS was $0.39 versus $0.26 expected. Free cash flow margin fell to 2.5% from 7.1% a year earlier. Shares dropped 5.1% to $9.73 after results.

Original reporting
Published Aug 6, 2026, 2:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 3:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Leggett & Platt’s (NYSE:LEG) Q2 CY2026 Sales Top Estimates But Stock Drops — source image
Decision brief

The 30-second read

$LEGNeutralMed
01

Why it matters

Traders should reconcile the earnings beat with weaker free cash flow margin and a modestly negative revenue outlook, which can drive valuation and positioning changes after results.

02

Market read

A classic post-earnings setup: headline beats versus cash flow quality and demand trajectory, producing a same-day downside reaction.

03

What to watch

Management attributes improved adjusted earnings to favorable items not expected to repeat, and the article highlights free cash flow margin deterioration (2.5% vs 7.1%), which may be the key risk for follow-through.

Relevance 7/10Novelty 6/10Timing: post-Q2 results, same-day reaction (shares down 5.1% to $9.73)

Background

Leggett & Platt is a diversified manufacturer; the article frames Q2 CY2026 as a beat on revenue and adjusted EPS amid declining sales trends.

Company-level read

Ticker impact

$LEGNeutralMedium confidence
Context

Leggett & Platt reported Q2 CY2026 revenue of $999.7M (1.7% above estimates) and adjusted EPS of $0.39 (48.6% above), yet shares fell 5.1% to $9.73.

Expected impact

Near-term volatility likely persists as investors weigh the beat against free cash flow margin deterioration and the outlook for revenue decline.

Evidence & confidence

The article provides a concrete earnings beat, a same-quarter free cash flow margin drop (2.5% vs 7.1%), and a forward revenue decline expectation (down 1.1% over 12 months), which together explain why the stock could drop despite headline EPS strength.

Market effects

Signals that diversified industrial/manufacturing peers may still face demand pressure even when earnings beats occur via cost discipline and non-recurring items.

No explicit regional demand or macro linkage provided in the article.

No explicit global supply chain or international demand drivers disclosed.

Counterpoint

The EPS and revenue beats, plus stable operating margin (8% in line with last year), suggest the selloff may overreact to cash flow optics rather than underlying profitability.

Key entities

  • Leggett & Platt

    Reported Q2 CY2026 revenue and adjusted EPS beats, but free cash flow margin fell sharply and shares dropped on the day.

  • Karl Glassman

    CEO attributed improved adjusted earnings to disciplined execution, cost management, and favorable items not expected to repeat.

Related articles

$LEGMedAI 8/10

Leggett & Platt Reports 2Q 2026 Results

Leggett & Platt (NYSE: LEG) reported 2Q 2026 sales of $1.0 billion, down 6% year over year, with 2Q EPS of $0.33 and adjusted EPS of $0.39. Adjusted EBIT rose to $89 million. The company cited weak bedding and consumer demand and said HSR waiting expired for its planned merger with Somnigroup (NYSE: SGI), pending shareholder and regulatory approvals.

$LEGMed

LEGGETT & PLATT INC (LEG): Results of Operations and Financial Condition

LEGGETT & PLATT INC (LEG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d121836dex991.htm PRESS RELEASE DATED AUGUST 6, 2026 PRESS RELEASE DATED AUGUST 6, 2026 EXHIBIT 99.1 FOR IMMEDIATE RELEASE: August 6, 2026 Leggett & Platt Reports 2Q 2026 Results Carthage, MO, August 6, 2026 — • 2Q sales of $1.0 billion, a 6% decrease vs 2Q25, including

$DTMedAI 8/10

Dynatrace Springs on Q1 Figures

Dynatrace (NYSE: DT) reported Q1 FY2027 results for the quarter ended June 30, 2026. Total ARR was $2,136 million, up 17%. Total revenue rose to $555 million, up 16%. Subscription revenue was $530 million. GAAP operating income was $71 million and non-GAAP $162 million. CEO Rick McConnell cited 41% organic net new ARR growth and accelerating TTM growth.

$DBXMed

Dropbox Shares Decline Despite Earnings Beat as Revenue Growth Disappoints

Dropbox (DBX) shares fell about 5% premarket to around $32.80 after Q2 2026 results. The company reported adjusted EPS of $0.75 vs $0.74 expected and revenue of $631.5M vs about $627M, but revenue rose only 0.9% year over year. Non-GAAP operating margin improved to 39.7%. Paying users reached 18.19M. William Blair upgraded to Market Perform, while consensus remains Sell.

$HLMedAI 8/10

Hecla Mining Q2 Earnings Call Highlights

Hecla Mining reported Q2 financial and operating updates. The company ended the quarter with $483 million cash, about $472 million net cash, and an essentially undrawn $225 million revolver. It projected 2026 free cash flow of about $500 million at $50 silver and $3,500 gold, and raised Greens Creek silver guidance to 8.0-8.3 million ounces. Production guidance was adjusted for Lucky Friday and Keno Hill.

$RCELHighAI 9/10

Avita Medical Shares Surge After Record Second-Quarter Performance

Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.